Dysregulation of MET signaling has been widely described in oncogenic processes. While all 3 types of MET dysregulation (amplification, overexpression, and gene mutations) have been documented in non-small cell lung cancer (NSCLC), MET exon 14 skipping alterations are a primary oncogenic driver in approximately 3% to 4% of these patients, often with a poor outcome. Join us as Dr. Paul Paik and Dr. Viola Zhu discuss the importance of testing patients for MET gene aberrations and their relevance in the management of NSCLC, especially as related to recently approved and emerging therapies for patients harboring a MET gene aberration.

Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.

The epigenetic modulator EZH2 is known to play a crucial role in mediating the lymphomagenesis of follicular lymphoma (FL), and the inhibition of EZH2 in the relapsing/refractory disease setting has shown efficacy. In this activity, Drs. Matasar and Nastoupil discuss the role of EZH2 in the pathobiology of FL, emphasize the need to test for mutations in EZH2 in FL, and explore the potential of targeting EZH2 in different settings of FL treatment.

BRAF mCRC is a very aggressive subset of colon cancer and, until recently, treatment options have been very limited. With a new standard of care on the rise, a critical challenge remains: How will emerging regimens be utilized in daily clinical practice?

Join us as 2 experts, Dr. Scott Kopetz and Dr. Julien Taieb, examine strategies to enhance the personalized management of patients with BRAF V600E-mutated mCRC.

Acromegaly is a rare disorder caused by excess growth hormone production and is associated with increased morbidity and mortality. Delays in the diagnosis and initiation of therapy or the provision of suboptimal therapy often negatively impact the quality of life of these patients. Join us for this expert interview with Dr. Susan Samson and Dr. Kevin Yuen who offer insights to help you overcome the complex medical challenges often faced when managing patients with acromegaly, including strategies to apply the latest guidelines and the 2020 consensus statement into clinical practice.

Do you face clinical challenges when managing patients with advanced HER2-positive gastric cancer? You’re not alone. Advanced gastroesophageal cancers remain among the most difficult cancers for clinicians to manage. One of the many challenges to optimizing patient outcomes is a relative lack of familiarity with practice standards regarding HER2-positive disease. While HER2 is an oncogenic driver in gastroesophageal cancers, it does not appear to act as a predictive biomarker in quite the same way as it does in breast cancer. However, there are ways to fully optimize anti-HER2 therapy in gastroesophageal cancers. Join us as Dr. Daniel Catenacci and Dr. Yelena Janjigian demystify HER2-positive gastroesophageal cancers and provide insights for the integration of personalized therapeutic approaches for these patients.

Have you ever wondered what went wrong in the management of invasive fungal infections? Through a storytelling approach Dr. James Lewis & Dr. George Thompson discuss a clinical story and identify where medical misses may have occurred. Supportive evidence will be provided on how care should have been provided and strategies for clinicians to apply in their practice.

With cases of COVID-19 surpassing 51 million worldwide, the rush to develop a vaccine capable of slowing the pandemic and lessening the morbidity and mortality of SARS-CoV-2 is underway. Several COVID-19 vaccines are now being studied in phase 3 trials, and clinicians would benefit from a review of these ongoing efforts, particularly the status of vaccines close to approval. This podcast will provide clinicians a review of up-to-date safety and efficacy information on vaccine candidates in late-stage development, and steps to prioritize patients who would benefit most from vaccination once available.

Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect. In this chapterized activity, Drs. Colbert, Toto, and Weir discuss strategies to manage a patient with chronic kidney disease (CKD) and resistant hypertension. Find out who is at risk for HK and explore the use of a potassium binder as both a short- and long-term solution.

Dr. Colin Quinn and Dr. Matthew Wicklund discuss the genetic and pathophysiologic underpinnings of limb girdle muscular dystrophy, as well as the use of appropriate diagnostic tests for accurate identification of LGMD.